





#### Invitation to the

# First National Meeting on Fibromuscular Dysplasia

## **Saturday 12<sup>th</sup> December 2015 9h00-16h00**

### **Auditoire Maisin**

(auditoires centraux de la Faculté de médecine de l'UCL) Avenue Emmanuel Mounier 51 - 1200 Brussels (see back cover for the map)

For information, please contact
Prof. Alexandre Persu (alexandre.persu@uclouvain.be)
or Prof. Patricia Van der Niepen
(Patricia.VanderNiepen@uzbrussel.be).

This meeting is supported by the Belgian Hypertension Committee and the Rare Disease Institute of the Cliniques Universitaires Saint-Luc.


Accreditation in Ethics and Economy has been requested.

This meeting has been organized with the support of









We are grateful to our sponsors

DAIICHI-SANKYO BAYER GENZYME

**DAIICHI-SANKYO s.a.**Mrs Sophie Allart
Rue Fond Jean Pâques 5
1348 Louvain-la-Neuve

Dear Colleagues from Belgium and abroad,

We are delighted to invite you to the first Belgian Meeting on Fibromuscular Dysplasia, a national meeting with a European and international faculty.

If you are nephrologist, cardiologist, neurologist, internist, paediatrician, radiologist, vascular surgeon, hypertension specialist or expert in vascular medicine, this meeting may be of interest for you.

Fibromuscular Dysplasia (FMD) needs to be revisited!

Did you know that:


- FMD lesions may be found in up to 5% of apparently healthy adults.
- In recent cohorts, the mean age at diagnosis is > 50 years, but FMD may also occur in children and elderly men.
- FMD is a systemic disease with frequent involvement of multiple vascular beds, including but not limited to renal and carotid arteries.
- FMD can be associated with spontaneous coronary artery dissection.
- FMD has an hereditary component and the first susceptibility genes are currently being identified.

Besides an update by some of the best experts of the disease from Belgium and abroad, this meeting will address important practical questions with pharmaco-economic and ethical relevance:

- When is it cost-effective to screen for FMD?
- Which is the best diagnostic algorithm?
- Should a patient with renal FMD be explored for cervical FMD and the reverse?
- When should angioplasty/surgery be considered?
- When is exploration of relatives justified?
- What should be done in case of incidental findings of FMD lesions?

Finally, the meeting will be an opportunity to present the BEL-FMD project, a Belgian multicentric cohort nested within a European initiative.

We look forward to meet you on 12th December 2015.



Prof. Patricia VAN DER NIEPEN

Nephrology Department Universitair Ziekenhuis Brussel Vriie Universiteit Brussel

Prof. Alexandre PERSU

Chairman of the ESH Working Group "Hypertension and the Kidney" Cardiology Department Cliniques Universitaires Saint-Luc Université Catholique de Louvain

### **National meeting on Fibromuscular Dysplasia PROGRAM**

09h00-09h25	Welcome coffee	
09h25-09h30	Introduction (A. Persu, UCL)	
09h30-10h00	The nephrologist's perspective (P. Van der Niepen, VUB) Discussants: P. de Leeuw (Maastricht) and G. Wuerzner (Lausanne)	
10h00-10h30	The neurologist's perspective (E. Touzé, Caen) Discussants: J. De Keyser (VUB) and A. Peeters (UCL)	
10h30-11h00	The cardiologist's perspective (P. Motreff, Clermont-Ferrand) Discussants: P. Chenu (UCL) and S. Gevaert (UGent)	
11h00-11h30	Coffee Break	
11h30-12h00	The patient's perspective (P. Mace, FMDSA, Ohio) Discussants: V. Godin and M. Bouwmeester (FMD groep Nederland)	
12h00-12h30	The European FMD consensus (A.Persu, UCL) Discussants: T. De Backer (UGent) and JP. Lengelé (GHDC/UCL)	
12h30-14h00	Lunch	
14h00-14h30	Why FMD needs to be revisited: lessons from registries (P-F. Plouin, Paris) Discussants: K.Claes (KUL) and J.C. Wautrecht (ULB)	
14h30-14h45	BEL-FMD : a national project nested within a European initiative (A. Persu, UCL)	
14h45-15h15	Strategies to unravel genes contributing to FMD (X. Jeunemaitre, Paris) Discussants: M. Vikkula (UCL) and J. Wang (Shanghai)	
15h15- 15h30	General discussion: towards a European registry and patient association Chairmen: JM. Krzesinski (ULg) and A. Morganti (Milano)	
15h30	Conclusion and take-home messages (P. Van der Niepen, VUB)	

5		
Š	<u> </u>	
	yo.be	
0 /00 00 0F /010 WH	sank	
	ich:	
	@da	
	hie.allart@daiichi-sank	
	phie.	
2	l (sop	
	our presence by e-mail (soph	
5	e by	
	sence	
5	r pre	
	noλ ι	
200	onfirm	
	2	

not attend meeting

 $\leq$ 

attend r

Fax Signature Address Phone Name

Please answer before 1st December 2015